Atwood, Brady K., Alex Straiker, and Ken Mackie. ‘CB2: Therapeutic Target-in-Waiting’. Progress in Neuro-Psychopharmacology and Biological Psychiatry 38.1 (2012): 16–20. Web.
Balon, Richard. ‘Mood, Anxiety, and Physical Illness: Body and Mind, or Mind and Body?’ Depression and Anxiety 23.6 (2006): 377–387. Web.
Brisbare-Roch, Catherine. ‘Promotion of Sleep by Targeting the Orexin System in Rats, Dogs and Humans’. 13.2 (2007): 150–155. Web. <http://www.nature.com.libproxy.ucl.ac.uk/nm/journal/v13/n2/pdf/nm1544.pdf>.
Carlos H. Schenck, Mark W. Mahowald. ‘Insights from Studying Human Sleep Disorders’. 437.7063 (2005): 1279–1285. Web. <http://www.nature.com.libproxy.ucl.ac.uk/nature/journal/v437/n7063/pdf/nature04287.pdf>.
Carvalho, Ana Franky, and Elisabeth J. Van Bockstaele. ‘Cannabinoid Modulation of Noradrenergic Circuits: Implications for Psychiatric Disorders’. Progress in Neuro-Psychopharmacology and Biological Psychiatry 38.1 (2012): 59–67. Web.
Cera, Nicoletta, Armando Tartaro, and Stefano L. Sensi. ‘Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study’. PLoS ONE 9.9 (2014): n. pag. Web.
Cryan, John F., and Klemens Kaupmann. ‘Don’t Worry “B” Happy!: A Role for GABAB Receptors in Anxiety and Depression’. Trends in Pharmacological Sciences 26.1 (2005): 36–43. Web.
Eric J. Olson, Kannan Ramar. ‘Management of Common Sleep Disorders’. 88.4 (2013): 231–238. Web. <http://www.aafp.org/afp/2013/0815/p231.pdf>.
Freund, Tamás F. ‘Interneuron Diversity Series: Rhythm and Mood in Perisomatic Inhibition’. Trends in Neurosciences 26.9 (2003): 489–495. Web.
H. Attarian, O Adenuga. ‘Treatment of Disorders of Hypersomnolence’. 16.9 302–302. Web. <http://download.springer.com/static/pdf/61/art%253A10.1007%252Fs11940-014-0302-9.pdf?auth66=1414068132_049751e80fe3aa485ba574ca1df01580&ext=.pdf>.
Hill, Andrew J. et al. ‘Phytocannabinoids as Novel Therapeutic Agents in CNS Disorders’. Pharmacology & Therapeutics 133.1 (2012): 79–97. Web.
Holmes, Andrew et al. ‘Neuropeptide Systems as Novel Therapeutic Targets for Depression and Anxiety Disorders’. Trends in Pharmacological Sciences 24.11 (2003): 580–588. Web.
Hoyer, Daniel, and Laura H. Jacobson. ‘Orexin in Sleep, Addiction and More: Is the Perfect Insomnia Drug at Hand?’ Neuropeptides 47.6 (2013): 477–488. Web.
Kalueff, Allan V., and David J. Nutt. ‘Role of GABA in Anxiety and Depression’. Depression and Anxiety 24.7 (2007): 495–517. Web.
Kilduff, Thomas S., and Christelle Peyron. ‘The Hypocretin/Orexin Ligand–Receptor System: Implications for Sleep and Sleep Disorders’. Trends in Neurosciences 23.8 (2000): 359–365. Web.
Levine, Joseph et al. ‘Anxiety Disorders and Major Depression, Together or Apart’. Depression and Anxiety 14.2 (2001): 94–104. Web.
Luscher, B, Q Shen, and N Sahir. ‘The GABAergic Deficit Hypothesis of Major Depressive Disorder’. Molecular Psychiatry 16.4 (2011): 383–406. Web.
Mahowald, Mark W., and Carlos H. Schenck. ‘Dissociated States of Wakefulness and Sleep’. Neurology 42 Suppl. 6 (1992): 44–52. Web. <http://ovidsp.uk.ovid.com/sp-3.29.1a/ovidweb.cgi?QS2=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>.
Mark W. Mahowald MD. ‘Pathophysiologic Mechanisms in REM Sleep Behavior Disorder’. Current Neurology and Neuroscience Reports 7.Issue 2 (2007): 167–172. Web. <http://link.springer.com.libproxy.ucl.ac.uk/article/10.1007/s11910-007-0013-7>.
N.P. Robertson, K.J. Peall. ‘Narcolepsy: Environment, Genes and Treatment’. 261.8 (2014): 1644–1646. Web. <http://link.springer.com.libproxy.ucl.ac.uk/article/10.1007/s00415-014-7435-3/fulltext.html>.
Saper, Clifford B., and Thomas E. Scammell. ‘Emerging Therapeutics in Sleep’. Annals of Neurology 74.3 (2013): 435–440. Web.
Smith, Kiersten S., and Uwe Rudolph. ‘Anxiety and Depression: Mouse Genetics and Pharmacological Approaches to the Role of GABAA Receptor Subtypes’. Neuropharmacology 62.1 (2012): 54–62. Web.
‘Sodium Oxybate: A Primer for Pharmacists in the Treatment of Narcolepsy’. N.p., n.d. Web. <https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf>.
Stores, G. ‘Medication for Sleep-Wake Disorders’. Archives of Disease in Childhood 88.10 (2003): 899–903. Web.
Strange, P. G. Brain Biochemistry and Brain Disorders. Oxford: Oxford University Press, 1992. Print.
